‘In vivo’ RNA-based gene editing model for blood disorders developed
Researchers from Penn Medicine and The Children’s Hospital of Philadelphia show that gene editing tools can be delivered via lipid nanoparticles, which would reduce cost and increase access to cutting-edge gene therapies.